Data showed Lilly’s neutralizing antibodies bamlanivimab and etesevimab reduced risk of COVID-19 hospitalizations and death by 70 percent
On Jan. 26, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.
Tags:
Source: Eli Lilly
Credit:
